Pediatrik onkoloji alan\u0131nda osteosarkom, \u00e7ocuklar ve ergenlerde en yayg\u0131n birincil malign kemik t\u00fcm\u00f6r\u00fc olarak tedavi zorluklar\u0131n\u0131 beraberinde getirmektedir. Bu agresif kanser t\u00fcr\u00fc, y\u00fcksek \u00e7o\u011falma h\u0131z\u0131 ve konvansiyonel tedavilere kar\u015f\u0131 diren\u00e7 geli\u015ftirme yetene\u011fi nedeniyle klinik a\u00e7\u0131dan b\u00fcy\u00fck bir engel te\u015fkil etmektedir. Son y\u0131llarda yap\u0131lan bilimsel \u00e7al\u0131\u015fmalar, N\u00fckleer fakt\u00f6r E2 ili\u015fkili fakt\u00f6r 2 (Nrf2) adl\u0131 bir transkripsiyon fakt\u00f6r\u00fcn\u00fc tedavi diren\u00e7 mekanizmalar\u0131nda kritik bir oyuncu olarak ortaya koymu\u015ftur. Nrf2\u2019nin hem koruyucu hem de t\u00fcm\u00f6r ilerlemesini destekleyen \u00e7ift y\u00f6nl\u00fc i\u015flevi, osteosarkomun kemoradyoterapiye kar\u015f\u0131 direncini anlamada yeni ufuklar a\u00e7maktad\u0131r.<\/p>\n
Nrf2, h\u00fccresel redoks dengeleyicisi olarak g\u00f6rev yapar ve h\u00fccreyi oksidatif strese kar\u015f\u0131 koruyan antioksidan genlerin ekspresyonunu d\u00fczenler. Antioxidant response element (ARE) yoluyla aktive olan Nrf2, sa\u011fl\u0131kl\u0131 h\u00fccreleri zararl\u0131 reaktif oksijen t\u00fcrlerinin (ROS) olumsuz etkilerinden koruyarak dokular\u0131n homeostaz\u0131n\u0131 sa\u011flar. Ancak kanser ortam\u0131nda bu koruyucu mekanizma, t\u00fcm\u00f6r h\u00fccrelerine hayatta kalma avantaj\u0131 kazand\u0131rmak \u00fczere k\u00f6t\u00fcye kullan\u0131lmaktad\u0131r. Osteosarkom h\u00fccrelerinde Nrf2\u2019nin a\u015f\u0131r\u0131 aktivasyonu, kemoterapi ve radyoterapi gibi klasik tedavilere kar\u015f\u0131 direnci g\u00fc\u00e7lendirmektedir.<\/p>\n
Nrf2\u2019nin kemoterapi direncini sa\u011flamadaki \u00f6nemli yollar\u0131ndan biri, h\u00fccre i\u00e7i ila\u00e7 konsantrasyonunu mod\u00fcle etmesidir. Bu d\u00fczenleme, \u00f6zellikle ATP-ba\u011flayan kasa (ABC) ailesine ait ila\u00e7 ta\u015f\u0131y\u0131c\u0131 proteinler ve indirgenmi\u015f folat ta\u015f\u0131y\u0131c\u0131 (RFC) proteinlerinin ekspresyonunu art\u0131rarak sa\u011flan\u0131r. B\u00f6ylece cisplatin, doksorubisin ve metotreksat gibi kemoterap\u00f6tik ajanlar\u0131n t\u00fcm\u00f6r h\u00fccreleri i\u00e7inde birikimi azal\u0131r, ila\u00e7lar\u0131n etkinli\u011fi d\u00fc\u015fer. Bu durum, Nrf2\u2019nin detoksifikasyon yollar\u0131n\u0131 da etkinle\u015ftirerek, malign h\u00fccrelerin zararl\u0131 bile\u015fenleri daha h\u0131zl\u0131 etkisiz hale getirmesine ve atmas\u0131na olanak tan\u0131r.<\/p>\n
Radyoterapi ile ind\u00fcklenen oksidatif stresin \u00fcstesinden gelmede de Nrf2 merkezi rol oynar. \u0130yonize radyasyonun temel \u00f6ld\u00fcr\u00fcc\u00fc etkisi, y\u00fcksek seviyede ROS olu\u015fumuyla DNA hasar\u0131n\u0131 tetiklemektir. Osteosarkom h\u00fccrelerinde Nrf2 aktivitesinin artmas\u0131, antioksidan enzimler ve DNA tamir mekanizmalar\u0131n\u0131n \u00fcretimini art\u0131rarak ROS kaynakl\u0131 hasar\u0131 h\u0131zla giderir. B\u00f6ylece DNA \u00e7ift sarmal k\u0131r\u0131klar\u0131n\u0131n tamiri sa\u011flan\u0131r, h\u00fccre \u00f6l\u00fcm\u00fc \u00f6nlenir ve t\u00fcm\u00f6r h\u00fccreleri radyoterapiye kar\u015f\u0131 diren\u00e7 kazan\u0131r. Bu s\u00fcre\u00e7, klinikte tedavi ba\u015far\u0131 oranlar\u0131n\u0131 ciddi \u015fekilde azalt\u0131r.<\/p>\n
Nrf2\u2019nin karma\u015f\u0131k d\u00fczenleme a\u011f\u0131nda kritik sinyal yollar\u0131 da yer almaktad\u0131r. Keap1-Nrf2-ARE ekseni, oksidatif stresi alg\u0131layan molek\u00fcler bir sens\u00f6r olarak i\u015flev g\u00f6r\u00fcr. Diren\u00e7li osteosarkomlarda bu eksenin bozularak s\u00fcrekli Nrf2 aktivasyonunun sa\u011fland\u0131\u011f\u0131 tespit edilmi\u015ftir. Ayr\u0131ca PI3K\/AKT sinyal yolu ile olan \u00e7apraz etkile\u015fimler, h\u00fccre hayatta kalma sinyallerini peki\u015ftirir ve metabolik yeniden programlamay\u0131 destekler. Bunlara ek olarak, otofaji s\u00fcreci de Nrf2 taraf\u0131ndan mod\u00fcle edilir; h\u00fccresel bile\u015fenlerin geri d\u00f6n\u00fc\u015f\u00fcm\u00fc ile hem t\u00fcm\u00f6r h\u00fccresinin sa\u011fkal\u0131m\u0131n\u0131 hem de \u00f6l\u00fcm\u00fc dengeler. Son d\u00f6nem ara\u015ft\u0131rmalar Nrf2\u2019nin ferroptozis gibi d\u00fczenlenmi\u015f h\u00fccre \u00f6l\u00fcm\u00fc mekanizmalar\u0131yla ili\u015fkili oldu\u011funu da g\u00f6stermekte, bu da Nrf2\u2019nin t\u00fcm\u00f6r kaderinde hem koruyucu hem de belirleyici bir rol oynad\u0131\u011f\u0131n\u0131 ortaya koymaktad\u0131r.<\/p>\n
Nrf2 sadece hayatta kalma yollar\u0131n\u0131 de\u011fil, t\u00fcm\u00f6r proliferasyonu ve metastaz\u0131 da etkiler. Y\u00fcksek Nrf2 ekspresyonu g\u00f6steren osteosarkom h\u00fccreleri, anabolik b\u00fcy\u00fcmeyi ve besin eksikli\u011fi gibi zor \u00e7evresel ko\u015fullara uyumu destekleyen metabolik esneklik kazan\u0131r. Bunun yan\u0131nda, Nrf2\u2019nin epitelden mezenkimal ge\u00e7i\u015f (EMT) s\u00fcrecini te\u015fvik etti\u011fi g\u00f6r\u00fclm\u00fc\u015f; bu da h\u00fccrelerin invazyon ve metastaz yeteneklerini art\u0131r\u0131p ikinci odaklar\u0131n olu\u015fumunu kolayla\u015ft\u0131r\u0131r. Klinik veriler, y\u00fcksek Nrf2 d\u00fczeyilerinin k\u00f6t\u00fc hasta prognozlar\u0131 ve d\u00fc\u015f\u00fck genel sa\u011fkal\u0131m ile korelasyon g\u00f6sterdi\u011fini ortaya koyarak bu fakt\u00f6r\u00fcn onkogenik potansiyelini do\u011frulamaktad\u0131r.<\/p>\n
Nrf2\u2019yi hedef alan tedavi stratejileri geli\u015ftirmek hayati fakat zorlu bir s\u00fcre\u00e7tir. \u00c7\u00fcnk\u00fc normal dokular\u0131 oksidatif hasardan koruyan Nrf2\u2019nin tam engellenmesi yan etkilere yol a\u00e7abilir. Buna ra\u011fmen, ML385 gibi se\u00e7ici inhibit\u00f6rlerin ke\u015ffi, t\u00fcm\u00f6r h\u00fccrelerini klasik kemoradyoterapiye kar\u015f\u0131 duyarl\u0131 hale getirmede umut vericidir. Ayr\u0131ca oridonin gibi do\u011fal bile\u015fiklerin \u00f6n klinik modelde Nrf2 arac\u0131l\u0131 diren\u00e7 mekanizmalar\u0131n\u0131 zay\u0131flatt\u0131\u011f\u0131 ve t\u00fcm\u00f6r gerilemesini tetikledi\u011fi g\u00f6zlemlenmi\u015ftir. Bu yakla\u015f\u0131mlar, t\u00fcm\u00f6r \u00f6zg\u00fc zafiyetleri hedeflerken sa\u011fl\u0131kl\u0131 h\u00fccrelerdeki koruyucu i\u015flevi koruma \u00e7abalar\u0131n\u0131n sembol\u00fc olarak g\u00f6r\u00fclmektedir.<\/p>\n
Nrf2\u2019nin \u00e7ok katmanl\u0131 fonksiyonlar\u0131n\u0131 \u00e7\u00f6zmek, osteosarkom biyolojisinin anla\u015f\u0131lmas\u0131nda paradigmatik bir de\u011fi\u015fim anlam\u0131na gelmektedir. Antioksidan savunman\u0131n fizyolojik homeostaz i\u00e7in elzem oldu\u011fu, ancak kanser h\u00fccrelerince suistimal edildi\u011finde tedavi ba\u015far\u0131s\u0131n\u0131n \u00f6n\u00fcnde ciddi bir engel olu\u015fturdu\u011fu art\u0131k netle\u015fmi\u015ftir. Ara\u015ft\u0131rmalar\u0131n bu molek\u00fcl\u00fcn d\u00fczenlenme ve etkile\u015fim a\u011flar\u0131na odaklanmas\u0131, diren\u00e7li osteosarkom alt tipleri i\u00e7in yenilik\u00e7i tedavi stratejilerinin geli\u015ftirilmesini sa\u011flayabilir.<\/p>\n
\u0130lerleyen d\u00f6nem \u00e7al\u0131\u015fmalar\u0131, Nrf2\u2019nin otofaji, ferroptozis ve metabolik plastisite \u00fczerindeki d\u00fczenleyici rol\u00fcn\u00fcn detayland\u0131r\u0131lmas\u0131na yo\u011funla\u015fmal\u0131d\u0131r. Bu \u00e7al\u0131\u015fmalar, Nrf2\u2019nin t\u00fcm\u00f6r bask\u0131lama ve te\u015fvik etme aras\u0131ndaki hassas dengesini ortaya koyarak, hayatta kalma yolaklar\u0131n\u0131 stratejik olarak hedefleyen kombinasyon tedavilerinin tasar\u0131m\u0131na rehberlik edecektir. Ayn\u0131 zamanda, ila\u00e7 ta\u015f\u0131ma sistemleri ve ki\u015fiselle\u015ftirilmi\u015f t\u0131p alan\u0131ndaki geli\u015fmeler, Nrf2 hedefli tedavilerin laboratuvardan klinik uygulamaya ge\u00e7i\u015finde b\u00fcy\u00fck potansiyel ta\u015f\u0131maktad\u0131r.<\/p>\n
Sonu\u00e7 olarak, Nrf2\u2019nin kemoradyoterapiye diren\u00e7teki \u00e7ift y\u00f6nl\u00fc etkisini anlamak, osteosarkomla m\u00fccadelede yeni bir d\u00f6nemi m\u00fcjdelemektedir. Bu molek\u00fcler temelleri \u00e7\u00f6zmek, pediatrik onkolojide bu agresif t\u00fcm\u00f6rle sava\u015fta daha etkili ve ki\u015fiselle\u015ftirilmi\u015f tedavi protokollerinin geli\u015ftirilmesine kap\u0131 aralamaktad\u0131r. Nrf2\u2019nin ayr\u0131nt\u0131l\u0131 incelenmesi, hastalar\u0131n genel sa\u011fkal\u0131m\u0131 ve ya\u015fam kalitesinde devrim yaratacak yeni tedavi yakla\u015f\u0131mlar\u0131n\u0131n habercisi olacakt\u0131r.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Pediatrik onkoloji alan\u0131nda osteosarkom, \u00e7ocuklar ve ergenlerde en yayg\u0131n birincil malign kemik t\u00fcm\u00f6r\u00fc olarak tedavi zorluklar\u0131n\u0131 beraberinde getirmektedir. Bu agresif kanser t\u00fcr\u00fc, y\u00fcksek \u00e7o\u011falma h\u0131z\u0131 ve konvansiyonel tedavilere kar\u015f\u0131 diren\u00e7 geli\u015ftirme yetene\u011fi nedeniyle klinik a\u00e7\u0131dan b\u00fcy\u00fck bir engel te\u015fkil etmektedir. Son y\u0131llarda yap\u0131lan bilimsel \u00e7al\u0131\u015fmalar, N\u00fckleer fakt\u00f6r E2 ili\u015fkili fakt\u00f6r 2 (Nrf2) adl\u0131 bir transkripsiyon…<\/p>\n","protected":false},"author":1,"featured_media":3364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[1963,1962,1965,1964,1966],"tmauthors":[],"class_list":{"0":"post-3363","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-kemoterapi-direncinde-nrf2-rolu","9":"tag-nrf2-osteosarkom-tedavi-direnci","10":"tag-nrf2-ve-hucresel-oksidatif-stres-korumasi","11":"tag-osteosarkom-kemoradyoterapi-direnci-mekanizmalari","12":"tag-pediatrik-osteosarkom-tedavi-zorluklari"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Nrf28217nin-Osteosarkom-Tedavi-Direncindeki-Rolu-1745246689.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3363"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3363\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3364"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3363"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nChemoradiotherapy resistance mechanisms in osteosarcoma focused on the role of Nuclear factor E2-related factor 2 (Nrf2).<\/p>\n
\nNrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma<\/p>\n
\n2024<\/p>\n
\nhttp:\/\/dx.doi.org\/10.1016\/j.gendis.2024.101335<\/p>\n
\nXianglin Peng, Jing Feng, Han Yang, Ping Xia, Feifei Pu, Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma, Genes & Diseases, Volume 12, Issue 4, 2025, 101335.<\/p>\n
\nGenes & Diseases<\/p>\n
\nOsteosarcoma, Nrf2, chemoradiotherapy resistance, antioxidant response element, drug efflux, DNA repair, reactive oxygen species, Keap1-Nrf2-ARE pathway, PI3K\/AKT signaling, autophagy, ferroptosis, tumor proliferation, metastasis<\/p>\n","protected":false},"excerpt":{"rendered":"